RU2018137032A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018137032A3 RU2018137032A3 RU2018137032A RU2018137032A RU2018137032A3 RU 2018137032 A3 RU2018137032 A3 RU 2018137032A3 RU 2018137032 A RU2018137032 A RU 2018137032A RU 2018137032 A RU2018137032 A RU 2018137032A RU 2018137032 A3 RU2018137032 A3 RU 2018137032A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662313334P | 2016-03-25 | 2016-03-25 | |
| US62/313,334 | 2016-03-25 | ||
| PCT/US2017/023126 WO2017165255A1 (en) | 2016-03-25 | 2017-03-20 | Pyrimidines and variants thereof, and uses therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018137032A RU2018137032A (en) | 2020-04-27 |
| RU2018137032A3 true RU2018137032A3 (en) | 2020-05-22 |
| RU2760733C2 RU2760733C2 (en) | 2021-11-30 |
Family
ID=59900805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018137032A RU2760733C2 (en) | 2016-03-25 | 2017-03-20 | Pyrimidines and their options, and their application |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10662162B2 (en) |
| EP (1) | EP3433258B1 (en) |
| JP (1) | JP6902045B2 (en) |
| KR (1) | KR102377805B1 (en) |
| CN (1) | CN108779119B (en) |
| AU (1) | AU2017237929B2 (en) |
| CA (1) | CA3018180C (en) |
| MA (1) | MA44489A (en) |
| MX (1) | MX384368B (en) |
| RU (1) | RU2760733C2 (en) |
| WO (1) | WO2017165255A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102489454B1 (en) | 2016-03-14 | 2023-01-17 | 애퍼런트 파마슈티컬스 인크. | Pyrimidines and variants thereof, and uses therefor |
| EP3433258B1 (en) | 2016-03-25 | 2023-07-19 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
| KR102454635B1 (en) | 2016-12-19 | 2022-10-17 | 노파르티스 아게 | Novel picolinic acid derivatives and their use as intermediates |
| CA3046027A1 (en) * | 2016-12-20 | 2018-06-28 | Prabha Ibrahim | Crystalline salts and polymorphs of a p2x3 antagonist |
| ES2980935T3 (en) * | 2017-11-01 | 2024-10-03 | Beijing Tide Pharmaceutical Co Ltd | P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition comprising it and its use |
| CN107778255B (en) * | 2017-11-16 | 2019-10-25 | 山东大学 | A kind of diarylpyrimidine HIV-1 reverse transcriptase inhibitor and its preparation method and application |
| JP7663508B2 (en) * | 2019-04-30 | 2025-04-16 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Methods of Treating Endometriotic Pain by Using Diaminopyrimidine Compounds |
| SG11202111877TA (en) * | 2019-04-30 | 2021-11-29 | Beijing Tide Pharmaceutical Co Ltd | Method for treating cough by using diaminopyrimidine compound |
| SG11202111907UA (en) | 2019-04-30 | 2021-11-29 | Beijing Tide Pharmaceutical Co Ltd | Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof |
| US20220332714A1 (en) * | 2019-06-06 | 2022-10-20 | Beijing Tide Pharmaceutical Co., Ltd. | P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition containing same, and use thereof |
| CN120058573A (en) * | 2025-04-29 | 2025-05-30 | 潍坊学院 | Synthesis method of 1-tribromomethylsulfonyl naphthalene and derivative thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2953567A (en) * | 1956-11-23 | 1960-09-20 | Burroughs Wellcome Co | 5-phenylmercaptopyrimidines and method |
| WO2000059893A1 (en) * | 1999-04-06 | 2000-10-12 | Krenitsky Pharmaceuticals Inc. | Neurotrophic thio substituted pyrimidines |
| EP1345927B1 (en) | 2000-12-21 | 2006-05-17 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| PL1725540T3 (en) * | 2004-03-05 | 2013-02-28 | Hoffmann La Roche | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
| BRPI0615613A2 (en) * | 2005-09-01 | 2009-05-19 | Hoffmann La Roche | diaminopyrimidines as p2x3 and p3x2 / 3 modulators |
| JP4850914B2 (en) * | 2005-09-01 | 2012-01-11 | エフ.ホフマン−ラ ロシュ アーゲー | Diaminopyrimidines as P2X3 and P2X2 / 3 modulators |
| EP1924564B1 (en) * | 2005-09-01 | 2016-11-09 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| JP4850913B2 (en) * | 2005-09-01 | 2012-01-11 | エフ.ホフマン−ラ ロシュ アーゲー | Diaminopyridines as P2X3 and P2X2 / 3 regulators |
| JP5128603B2 (en) * | 2006-10-04 | 2013-01-23 | エフ.ホフマン−ラ ロシュ アーゲー | Method for the synthesis of phenoxydiaminopyrimidine derivatives |
| WO2008104472A1 (en) | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| CA2699631A1 (en) * | 2007-10-31 | 2009-05-07 | Nissan Chemical Industries, Ltd. | Pyridazinone compounds and p2x7 receptor inhibitors |
| GB2471713A (en) * | 2009-07-08 | 2011-01-12 | Univ Greenwich | 1,2,4-triazine derivatives and their use as sodium channel blockers |
| TWI637949B (en) * | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | Aminotriazine derivative and pharmaceutical composition comprising the same |
| SG11201601145RA (en) * | 2013-08-23 | 2016-03-30 | Afferent Pharmaceuticals Inc | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough |
| EP3981406A1 (en) * | 2014-07-03 | 2022-04-13 | Afferent Pharmaceuticals Inc. | Methods and compositions for treating diseases and conditions |
| KR102489454B1 (en) * | 2016-03-14 | 2023-01-17 | 애퍼런트 파마슈티컬스 인크. | Pyrimidines and variants thereof, and uses therefor |
| EP3433258B1 (en) | 2016-03-25 | 2023-07-19 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
-
2017
- 2017-03-20 EP EP17770880.7A patent/EP3433258B1/en active Active
- 2017-03-20 CN CN201780019534.0A patent/CN108779119B/en active Active
- 2017-03-20 MA MA044489A patent/MA44489A/en unknown
- 2017-03-20 WO PCT/US2017/023126 patent/WO2017165255A1/en not_active Ceased
- 2017-03-20 US US16/080,840 patent/US10662162B2/en active Active
- 2017-03-20 AU AU2017237929A patent/AU2017237929B2/en active Active
- 2017-03-20 MX MX2018011622A patent/MX384368B/en unknown
- 2017-03-20 RU RU2018137032A patent/RU2760733C2/en active
- 2017-03-20 KR KR1020187029805A patent/KR102377805B1/en active Active
- 2017-03-20 JP JP2018549444A patent/JP6902045B2/en active Active
- 2017-03-20 CA CA3018180A patent/CA3018180C/en active Active
-
2020
- 2020-04-13 US US16/846,452 patent/US11230532B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3433258A1 (en) | 2019-01-30 |
| RU2018137032A (en) | 2020-04-27 |
| KR20180128015A (en) | 2018-11-30 |
| US11230532B2 (en) | 2022-01-25 |
| MX2018011622A (en) | 2019-03-28 |
| KR102377805B1 (en) | 2022-03-22 |
| CN108779119A (en) | 2018-11-09 |
| AU2017237929A1 (en) | 2018-09-13 |
| WO2017165255A1 (en) | 2017-09-28 |
| US10662162B2 (en) | 2020-05-26 |
| MA44489A (en) | 2019-01-30 |
| JP2019510025A (en) | 2019-04-11 |
| US20190055202A1 (en) | 2019-02-21 |
| BR112018069105A2 (en) | 2019-01-29 |
| CA3018180A1 (en) | 2017-09-28 |
| RU2760733C2 (en) | 2021-11-30 |
| AU2017237929B2 (en) | 2021-04-15 |
| MX384368B (en) | 2025-03-14 |
| EP3433258B1 (en) | 2023-07-19 |
| JP6902045B2 (en) | 2021-07-14 |
| CA3018180C (en) | 2024-02-20 |
| CN108779119B (en) | 2022-02-08 |
| US20200239421A1 (en) | 2020-07-30 |
| EP3433258A4 (en) | 2019-10-30 |